HTA of meniscal allograft transplantation for post-meniscectomy syndrome in Austria

15

Oct 2018

On 20th of July, 2018, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI) has published HTA of meniscal allograft transplantation for post-meniscectomy syndrome in Austria.

Post-meniscectomy syndrome is broadly characterized by intractable pain following the partial or total removal of a meniscus. Removal of a meniscus can lead to joint instability, increased risk of osteoarthritis, and eventually total joint replacement.

Meniscal allograft transplantation (MAT) involves the transplant of a cadaveric meniscal allograft into the knee of a patient who has had a prior (sub)total meniscectomy. The transplanted allograft is intended to be permanent and aims to restore the load-bearing and shock absorption function provided by the meniscus. In theory, MAT is proposed to relieve the pain and swelling associated with the post-meniscectomy syndrome, lower the risk of progression to osteoarthritis, and prolong the need for a total knee replacement and associated revisions.

The authors have conducted a systematic search of the literature in order to assess whether meniscus allograft transplantation is more effective concerning changes in pain, changes in function, and necessity of total joint replacement, as well as safety (concerning complications and transplant failure) in comparison to conservative management The literature was searched on Medline, Embase, Cochrane Library and the University of York Centre for Reviews and Dissemination.

One (1) non-randomised comparative study with 36 patients was identified regarding the effectiveness of MAT, while five (5) prospective case series with a total of 308 patients were identified regarding the safety of MAT.

Regarding the clinical effectiveness, the authors have revealed that the change in patient-reported pain was significantly improved in the MAT group compared to conservative management at 12 months (MD 15.1, 95% CI 2.4 to 27.8, p=0.021). Regarding function, MAT demonstrates partly significantly better improvements. Quality of life showed both clinically significant and statistically significant increases in the MAT group.

Regarding the safety, there were no significant differences in complications comparing with conservative management. Nearly all difficulties with MAT required re-operations.

The authors conclude that there is not enough evidence demonstrating benefits in order to include MAT into the Austrian benefit catalogue.

See the full report in English (with summary in German) here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more